We’re developing targeted therapies to lower LDL cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, complementary, once-daily, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C.

learn more


Setting the Record Straight: The Facts About Bempedoic Acid

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the… more

Posted by mlowe@esperion.com

Cardiovascular Disease Awareness: Heart Healthy Initiatives Underway at Esperion

I am very excited to join my Esperion colleagues, their families and pets to participate in the Washtenaw County American… more

Posted by mlowe@esperion.com

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C…. more

Posted by mlowe@esperion.com